Document is current
Any future updates will be listed below
-
Authors
Beattie, Jason https://orcid.org/0000-0002-8225-2425
Rizvi, Hira
Fuentes, Paige
Luo, Jia https://orcid.org/0000-0003-3606-827X
Schoenfeld, Adam
Lin, I-Hsin
Postow, Michael
Callahan, Margaret
Voss, Martin H https://orcid.org/0000-0003-0551-5807
Shah, Neil J
Betof Warner, Allison
Chawla, Mohit
Hellmann, Matthew D
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04438382 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
- License Information
